N@N

Vamil Divan Reiterated (ABBV) at Strong Buy and Held Target at $131 on, Sep 1st, 2021

Vamil Divan of Mizuho, Reiterated "AbbVie Inc." (ABBV) at Strong Buy and Held Target at $131 on, Sep 1st, 2021.

Vamil has made no other calls on ABBV in the last 4 months.

There are 8 other peers that have a rating on ABBV. Out of the 8 peers that are also analyzing ABBV, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $119 on, Monday, August 2nd, 2021

These are the ratings of the 7 analyists that currently disagree with Vamil

---

• Steve Scala of "TD Cowen" Maintained at Buy with Increased Target to $130 on, Monday, August 23rd, 2021
• Geoffrey Porges of "SVB Leerink" Maintained at Buy with Increased Target to $148 on, Friday, August 20th, 2021
• Robyn Karnauskas of "Truist Securities" Initiated at Strong Buy and Held Target at $118 on, Monday, July 26th, 2021
• Navin Jacob of "UBS" Maintained at Strong Buy with Increased Target to $126 on, Wednesday, May 12th, 2021
• Daniel Busby of "RBC Capital" Reiterated at Buy and Held Target at $135 on, Monday, May 3rd, 2021
• Gary Nachman of "BMO Capital" Maintained at Buy with Increased Target to $129 on, Monday, May 3rd, 2021
• Tim Anderson of "Wolfe Research" Maintained at Buy with Increased Target to $127 on, Monday, May 3rd, 2021

Contributing Sources

---